We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002064
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition Intervention
Toxoplasmosis, Cerebral HIV Infections Drug: Pyrimethamine Drug: Clindamycin

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions are excluded:

  • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.

Patients with other opportunistic infections or brain diseases are excluded.

Patients with AIDS and cerebral toxoplasmosis.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002064


Locations
United States, California
Palo Alto Med Foundation
Palo Alto, California, United States, 94301
Sponsors and Collaborators
Palo Alto Medical Foundation
  More Information

ClinicalTrials.gov Identifier: NCT00002064     History of Changes
Other Study ID Numbers: 021A
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: June 1989

Keywords provided by NIH AIDS Clinical Trials Information Service:
Sulfonamides
Toxoplasmosis
AIDS-Related Opportunistic Infections
Pyrimethamine
Drug Therapy, Combination
Encephalitis
Acquired Immunodeficiency Syndrome
Clindamycin

Additional relevant MeSH terms:
HIV Infections
Encephalitis
Toxoplasmosis
Toxoplasmosis, Cerebral
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Coccidiosis
Protozoan Infections
Parasitic Diseases
Brain Abscess
Abscess
Suppuration
Infection
Central Nervous System Protozoal Infections
Central Nervous System Parasitic Infections
Central Nervous System Infections
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Pyrimethamine
Anti-Bacterial Agents


To Top